Table 4.
Distribution of AML96 DSIL patients with the GFI136S or GFI136N form, respectively, in morphological AML subtypes as defined in the FAB classification
| FAB subgroup | GFI136S% (no. of all cases) | GFI1S36N% (no. of all cases) | P |
|---|---|---|---|
| M0 (17) | 88 (15) | 12 (2) | .69 |
| M1 (79) | 90 (71) | 10 (8) | 1 |
| M2 (132) | 89 (117) | 11 (15) | .723 |
| M4 (48) | 98 (47) | 2 (1) | .046 |
| M4eo (21) | 91 (19) | 10 (2) | 1 |
| M5a (51) | 92 (47) | 8 (4) | .629 |
| M5b (14) | 71 (10) | 29 (4) | .043 |
| M6 (8) | 75 (6) | 25 (2) | .197 |
| M7 (4) | 75 (3) | 25 (1) | .355 |
| RAEB-T (2) | 100 (2) | 0 | 1 |
| Total (377) | 89 | 11 |
By the use of a mosaic analysis, no significant difference could be observed between patients carrying the 2 GFI1 variants.
AML indicates acute myeloid leukemia; DSIL, Deutsche Studieninitiative Leukämie; FAB, French-American-British; and GFI1, Growth Factor Independence 1.